Studie ke zkoumání účinnosti a bezpečnosti anifrolumabu u dospělých s chronickým a/nebo subakutním kožním lupus erythematodes (LAVENDER)
Multicentrická, randomizovaná, dvojitě zaslepená, placebem kontrolovaná studie fáze III k vyhodnocení účinnosti a bezpečnosti anifrolumabu u dospělých s chronickým a/nebo subakutním kožním lupus erythematodes, kteří jsou refrakterní a/nebo netolerují antimalarickou terapii
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
This is a multicenter, randomized, double-blind, placebo-controlled, Phase III study to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute CLE who are refractory and/or intolerant to antimalarial therapy. The study has a randomized, 24-week double-blind, placebo-controlled study period (Week 0 to Week 23), to evaluate the efficacy and safety of anifrolumab. The double-blind study period will be followed by an open-label, uncontrolled treatment period in which all participants will receive treatment with anifrolumab from Week 24 to Week 51. After the open-label treatment period, participants will enter a 12-week Safety Follow-up Period.
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
-
Ciudad de Buenos Aires, Argentina, 1221
- Research Site
-
Córdoba, Argentina, 5000
- Research Site
-
Córdoba, Argentina, X5004BAL
- Research Site
-
Quilmes, Argentina, 1878
- Research Site
-
San Miguel, Argentina, 1663
- Research Site
-
-
-
-
-
Kogarah, Austrálie, 3168
- Research Site
-
Melbourne, Austrálie, 3004
- Research Site
-
Mitcham, Austrálie, 3132
- Research Site
-
Westmead, Austrálie, 2145
- Research Site
-
Woolloongabba, Austrálie, 04102
- Research Site
-
-
-
-
-
Belo Horizonte, Brazílie, 30150-221
- Research Site
-
Porto Alegre, Brazílie, 90035903
- Research Site
-
Rio de Janeiro, Brazílie, 22470-220
- Research Site
-
Salvador, Brazílie, 40150-150
- Research Site
-
São Paulo, Brazílie, 05403-000
- Research Site
-
-
-
-
-
Sofia, Bulharsko, 1784
- Research Site
-
Sofia, Bulharsko, 1463
- Research Site
-
Sofia, Bulharsko, 1528
- Research Site
-
-
-
-
-
Osorno, Chile, 200025
- Research Site
-
Santiago, Chile, 7500571
- Research Site
-
Santiago, Chile, 130021
- Research Site
-
-
-
-
-
Aarhus, Dánsko, 641-8510
- Research Site
-
Copenhagen, Dánsko, 2100
- Research Site
-
-
-
-
-
Iloilo City, Filipíny, 5000
- Research Site
-
Lipa, Filipíny, 4217
- Research Site
-
Manila, Filipíny, 1000
- Research Site
-
-
-
-
-
Bois-Guillaume, Francie, 76031
- Research Site
-
Dijon, Francie, 21000
- Research Site
-
Lyon, Francie, 69437
- Research Site
-
Montivilliers, Francie, 76290
- Research Site
-
Nantes, Francie, 44000
- Research Site
-
Paris, Francie, 75010
- Research Site
-
Paris, Francie, 75014
- Research Site
-
Paris, Francie, 75013
- Research Site
-
Paris, Francie, 75970
- Research Site
-
Poitiers, Francie, 86000, FR
- Research Site
-
Toulouse, Francie, 31059
- Research Site
-
-
-
-
-
Breda, Holandsko, 4818 CK
- Research Site
-
Rotterdam, Holandsko, 3015 GD
- Research Site
-
-
-
-
-
Brescia, Itálie, 25123
- Research Site
-
Cona, Itálie, 44124
- Research Site
-
Florence, Itálie, 50121
- Research Site
-
Milan, Itálie, 20132
- Research Site
-
Naples, Itálie, 80138
- Research Site
-
Reggio Emilia, Itálie, 42123
- Research Site
-
Roma, Itálie, 00144
- Research Site
-
Rome, Itálie, 00168
- Research Site
-
-
-
-
-
Chūōku, Japonsko, 104-8560
- Research Site
-
Fukuoka, Japonsko, 812-8582
- Research Site
-
Kanazawa, Japonsko, 920-8641
- Research Site
-
Kita-gun, Japonsko, 761-0793
- Research Site
-
Nagoya, Japonsko, 457-8510
- Research Site
-
Nagoya, Japonsko, 467-8602
- Research Site
-
Wakayama, Japonsko, 641-8510
- Research Site
-
Yokohama, Japonsko, 232-0024
- Research Site
-
tabashi City, Japonsko, 173-8606
- Research Site
-
-
-
-
-
Cape Town, Jižní Afrika, 7500
- Research Site
-
Johannesburg, Jižní Afrika, 2193
- Research Site
-
-
-
-
-
Seoul, Jižní Korea, 03080
- Research Site
-
Seoul, Jižní Korea, 06591
- Research Site
-
Seoul, Jižní Korea, 06973
- Research Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 1M9
- Research Site
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8N 3Z5
- Research Site
-
Toronto, Ontario, Kanada, M5T 2S8
- Research Site
-
-
-
-
-
Barranquilla, Kolumbie, 080020
- Research Site
-
Bogotá, Kolumbie, 110221
- Research Site
-
-
-
-
-
Guadalajara, Mexiko, 44340
- Research Site
-
Guadalajara, Mexiko, 44610
- Research Site
-
Mexico City, Mexiko, 07760
- Research Site
-
Veracruz, Mexiko, 91910
- Research Site
-
-
-
-
-
Papatoetoe, Nový Zéland, 2025
- Research Site
-
-
-
-
-
Berlin, Německo, 10117
- Research Site
-
Bochum, Německo, 44791
- Research Site
-
Dresden, Německo, 01307
- Research Site
-
Erlangen, Německo, 91054
- Research Site
-
Essen, Německo, 45147
- Research Site
-
Freiburg im Breisgau, Německo, 79104
- Research Site
-
Hanover, Německo, 30625
- Research Site
-
Kiel, Německo, 24105
- Research Site
-
Leipzig, Německo, 04103
- Research Site
-
Mainz, Německo, 55131
- Research Site
-
Marburg, Německo, 35043
- Research Site
-
Regensburg, Německo, 93053
- Research Site
-
Wuppertal, Německo, 42283
- Research Site
-
-
-
-
-
Katowice, Polsko, 40-851
- Research Site
-
Kielce, Polsko, 25-316
- Research Site
-
Ossy, Polsko, 40-027
- Research Site
-
Rzeszów, Polsko, 35-055
- Research Site
-
Warsaw, Polsko, 02-637
- Research Site
-
-
-
-
-
Braga, Portugalsko, 4710-243
- Research Site
-
Lisbon, Portugalsko, 1649-035
- Research Site
-
Porto, Portugalsko, 4099-001
- Research Site
-
-
-
-
-
Graz, Rakousko, 8036
- Research Site
-
Innsbruck, Rakousko, 6020
- Research Site
-
Linz, Rakousko, 4020
- Research Site
-
Vienna, Rakousko, 1130
- Research Site
-
-
-
-
-
Bucharest, Rumunsko, 020125
- Research Site
-
Iași, Rumunsko, 700291
- Research Site
-
-
-
-
-
Košice, Slovensko, 04001
- Research Site
-
Piešťany, Slovensko, 92101
- Research Site
-
-
-
-
-
Cambridge, Spojené království, CB2 0QQ
- Research Site
-
Leeds, Spojené království, LS2 9JT
- Research Site
-
London, Spojené království, NW1 2PG
- Research Site
-
London, Spojené království, SE5 9RS
- Research Site
-
London, Spojené království, SE1 7EH
- Research Site
-
London, Spojené království, NW3 2QG
- Research Site
-
Newcastle upon Tyne, Spojené království, NE1 4LP
- Research Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Spojené státy, 85028
- Research Site
-
-
California
-
Covina, California, Spojené státy, 91722
- Research Site
-
La Jolla, California, Spojené státy, 92037
- Research Site
-
Los Angeles, California, Spojené státy, 90045
- Research Site
-
Los Angeles, California, Spojené státy, 90089
- Research Site
-
Orange, California, Spojené státy, 92868
- Research Site
-
San Francisco, California, Spojené státy, 94143
- Research Site
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80045
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, Spojené státy, 06519
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Spojené státy, 20037
- Research Site
-
-
Florida
-
Fort Lauderdale, Florida, Spojené státy, 33309
- Research Site
-
Miami, Florida, Spojené státy, 33174
- Research Site
-
Plantation, Florida, Spojené státy, 33324
- Research Site
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60637
- Research Site
-
Chicago, Illinois, Spojené státy, 60611
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46202
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21287
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02114
- Research Site
-
Boston, Massachusetts, Spojené státy, 02115-5817
- Research Site
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48109
- Research Site
-
Bloomfield Hills, Michigan, Spojené státy, 48302
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, Spojené státy, 55905
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Spojené státy, 68198-5885
- Research Site
-
-
New York
-
New York, New York, Spojené státy, 10028
- Research Site
-
Rochester, New York, Spojené státy, 14642
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Spojené státy, 28207
- Research Site
-
Statesville, North Carolina, Spojené státy, 28625
- Research Site
-
-
Ohio
-
Cleveland, Ohio, Spojené státy, 44195
- Research Site
-
-
Oregon
-
Portland, Oregon, Spojené státy, 97239
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, Spojené státy, 02903
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29425
- Research Site
-
-
Texas
-
Dallas, Texas, Spojené státy, 75390-8843
- Research Site
-
-
Virginia
-
Charlottesville, Virginia, Spojené státy, 22903
- Research Site
-
Roanoke, Virginia, Spojené státy, 24016
- Research Site
-
-
-
-
-
Belgrade, Srbsko, 11000
- Research Site
-
Kragujevac, Srbsko, 34000
- Research Site
-
-
-
-
-
Kaohsiung City, Tchaj-wan, 83301
- Research Site
-
Taichung, Tchaj-wan, 404
- Research Site
-
Taipei, Tchaj-wan, 10449
- Research Site
-
-
-
-
-
Bangkok, Thajsko, 10330
- Research Site
-
Bangkok, Thajsko, 10700
- Research Site
-
Hat Yai, Thajsko, 90110
- Research Site
-
Khlong Luang, Thajsko, 12120
- Research Site
-
Khon Kaen, Thajsko, 40002
- Research Site
-
-
-
-
-
Cordaleo, Turecko (Türkiye), 35575
- Research Site
-
Istanbul, Turecko (Türkiye), 34098
- Research Site
-
Kayseri, Turecko (Türkiye), 38039
- Research Site
-
Samsun, Turecko (Türkiye), 55270
- Research Site
-
-
-
-
-
Changchun, Čína, 130021
- Research Site
-
Changsha, Čína, 410011
- Research Site
-
Chengdu, Čína, 610021
- Research Site
-
Chongqing, Čína, 400016
- Research Site
-
Dongguan, Čína, 523059
- Research Site
-
Guangzhou, Čína, 510120
- Research Site
-
Heilongjiang, Čína, 150086
- Research Site
-
Jinan, Čína, 250022
- Research Site
-
Shanghai, Čína, 200025
- Research Site
-
Shanghai, Čína, 200443
- Research Site
-
Shenzhen, Čína, 518053
- Research Site
-
Shenzhen, Čína, 518020
- Research Site
-
Shenzhen, Čína, 518052
- Research Site
-
Zhuzhou, Čína, 412007
- Research Site
-
Ürümqi, Čína, CN-830004
- Research Site
-
-
-
-
-
Athens, Řecko, 12462
- Research Site
-
Athens, Řecko, 16121
- Research Site
-
-
-
-
-
Barcelona, Španělsko, 8035
- Research Site
-
Barcelona, Španělsko, 08025
- Research Site
-
Castellon, Španělsko, 12004
- Research Site
-
Granada, Španělsko, 18012
- Research Site
-
L'Hospitalet de Llobregat, Španělsko, 08907
- Research Site
-
Las Palmas de Gran Canaria, Španělsko, 35010
- Research Site
-
Madrid, Španělsko, 28034
- Research Site
-
Madrid, Španělsko, 28041
- Research Site
-
Madrid, Španělsko, 28040
- Research Site
-
Madrid, Španělsko, 28006
- Research Site
-
Majadahonda, Španělsko, 28222
- Research Site
-
Salamanca, Španělsko, 37007
- Research Site
-
Seville, Španělsko, 41014
- Research Site
-
Valencia, Španělsko, 46014
- Research Site
-
Valencia, Španělsko, 46017
- Research Site
-
Vigo, Španělsko, 36200
- Research Site
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Key inclusion criteria:
-
Participants must have a confirmed diagnosis of CLE. Diagnosis must be clinically and histologically confirmed with the following:
- CLASI-A total score ≥ 10 points at Screening and confirmed at randomization.
- Inadequate response or intolerant to antimalarial therapy.
-
Participants should have no medical history or signs or symptoms of active or prior tuberculosis infection (TB) and the same should reflect in chest radiograph or a chest CT scan result.
-
Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Key exclusion criteria:
- History or evidence of suicidal ideation.
- Severe or life-threatening Systemic lupus erythematosus (SLE).
- Active SLE or Sjögren's Syndrome.
- Any active skin conditions other than CLE that may interfere with the study.
- History of, or current diagnosis of, catastrophic antiphospholipid syndrome (APS).
- History of recurrent infection requiring hospitalization and IV antibiotics.
- COVID-19 infection.
- Any history of an anaphylactic reaction to human proteins, or monoclonal antibodies.
- At screening, if participants do not meet the eligibility criteria assessed based on laboratory test results e.g tests for total bilirubin, serum creatinine etc.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Anifrolumab
Participants will receive anifrolumab as a SC injection from Week 0/Day 1 up to Week 51. |
Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS). |
|
Komparátor placeba: Placebo
Participants will receive placebo as a SC injection from Week 0/Day 1 up to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51. |
Matching placebo solution for injection in aPFS. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score
Časové okno: At Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. It consists of 2 separate scores: i) activity of the disease, and ii) measure of damage. The CLASI instrument will be used at each study visit to capture individual skin manifestation scores. CLASI-70 responder (Yes/No) is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 24
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change from baseline in total CLASI-A score
Časové okno: At Week 24
|
The CLASI-A is a validated index used for assessing the cutaneous lesions of SLE. |
At Week 24
|
|
Number of participants with CLASI-70 response
Časové okno: At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 12
|
|
Number of participants with ≥ 7-point reduction from baseline in CLASI-A total score
Časové okno: At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. A 7-point reduction CLASI-A is established as clinically meaningful improvement in disease for CLE and as being impactful for patients. |
At Week 12
|
|
Number of participants with CLASI-50 response
Časové okno: At Week 12 and Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-50 responder is defined as a responder (yes/no) is defined as a participant who achieves at least a 50% reduction relative to baseline in CLASI-A score. Otherwise, the participant is a non-responder. |
At Week 12 and Week 24
|
|
Number of participants who are sustained CLASI-70 responders
Časové okno: Up to Week 52
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. Amongst participants randomized to anifrolumab, the number of participants who maintained a CLASI-70 response from Week 24 up to Week 52 will be evaluated. |
Up to Week 52
|
|
Serum trough (pre-dose) concentrations of anifrolumab
Časové okno: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
The Ctrough of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
|
Number of participants with positive antidrug antibody
Časové okno: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The immunogenicity of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Percent change from baseline in suppression of the Interferon 21-gene
Časové okno: Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The pharmacodynamics of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Change from baseline in Skindex-29+3 Symptom domain scores
Časové okno: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. The instrument consists of 33 items, which are used to calculate 4 domains: Symptoms (7 items), Emotions (10 items), Functioning (12 items), and Lupus-specific (3 items). The remaining item asks the participants to rate how often they worry about side effects from treatment; however, this item is not used to calculate the domain scores. The response options are on a 5-point verbal rating scale, ranging from 1 (Never) to 5 (All the time). The instrument has a recall period of the previous 4 weeks. Each domain score ranges from 0 to 100 points, with higher scores indicating worse health-related quality of life. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Emotion domain scores
Časové okno: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Function domain scores
Časové okno: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Lupus-Specific domain scores
Časové okno: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Total score
Časové okno: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Time from IP start date to CLASI-70 response.
Časové okno: From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
|
Time from IP start date to CLASI-50 response.
Časové okno: From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
Další výstupní opatření
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of participants with adverse events
Časové okno: Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
To evaluate the safety and tolerability of anifrolumab compared with placebo in participants with CLE. |
Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- D346BC00001
- 2021-003698-70 (Číslo EudraCT)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Časový rámec sdílení IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Kritéria přístupu pro sdílení IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .